Compound Information | SONAR Target prediction |
Name: | 2`,3`-dideoxycytidine |
Unique Identifier: | LOPAC 00842 |
MolClass: | Checkout models in ver1.5 and ver1.0 |
Molecular Formula: | C9H13N3O3 |
Molecular Weight: | 198.115 g/mol |
X log p: | 2.587 (online calculus) |
Lipinksi Failures | 0 |
TPSA | 41.9 |
Hydrogen Bond Donor Count: | 0 |
Hydrogen Bond Acceptors Count: | 6 |
Rotatable Bond Count: | 2 |
Canonical Smiles: | NC1C=CN(C2CCC(CO)O2)C(=O)N=1 |
Class: | Immune System |
Action: | Inhibitor |
Selectivity: | Reverse Transcriptase |
Generic_name: | Zalcitabine |
Chemical_iupac_name: | 4-amino-1-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidin-2-one |
Drug_type: | Approved Drug |
Pharmgkb_id: | PA451950 |
Kegg_compound_id: | C07207 |
Drugbank_id: | APRD00562 |
Melting_point: | 210 - 214 oC |
H2o_solubility: | 2.42E+004 mg/L |
Logp: | -0.964 |
Cas_registry_number: | 7481-89-2 |
Drug_category: | Anti-HIV Agents; Antimetabolites; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; ATC:J05AF03 |
Indication: | For the treatment of Human immunovirus (HIV) infections. |
Pharmacology: | Zalcitabine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. |
Mechanism_of_action: | Zalcitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Zalcitabine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3--OH group in the incorporated nucleoside analogue prevents the formation of the 5- to 3- phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. |
Organisms_affected: | Human immunodeficiency virus |